| |
|
|
|
CfPA-The Center for Professional Advancement, Burlingame, CA
October 24-25, 2016
Who Should Attend?
This course is intended for individuals who have the responsibility for establishing the stability of Over-the-Counter (OTC) drug products. This course will benefit individuals in:
• R&D
• QA/QC
• Technical Operations
• Contract Laboratories
RAPS - Regulatory Affairs Professional Society
This course has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's recertification of their Regulatory Affairs Certification (RAC) upon full completion. Course Description
|
|
|
|
|
|
|
|
Organized by:
|
|
CfPA-The Center for Professional Advancement |
|
|
Invited Speakers:
|
|
| David E. Wiggins; Sr. Associate Director of Analytical Development, Bayer Consumer Care |
David E. Wiggins is Sr. Associate Director of Analytical Development for Bayer Consumer Care with responsibility for pre-market stability, analytical method validation and method transfer.
Prior to joining Bayer, Mr. Wiggins worked for Schering- Plough and Merck with responsibility for Method Optimization, Method Validation, Method Transfer and Stability (both preand post-market). These responsibilities have additionally included involvement with multiple NDA submissions and FDA general and PAI inspections.
Mr. Wiggins has over 30 years experience in the pharmaceutical industry in both a QC and an R&D setting. During this time, he has been instrumental in establishing and updating stability and method validation policy to be consistent with the changing regulatory requirements. Mr. Wiggins has frequently lectured on stability and analytical method validation in the US, Puerto Rico, and throughout Europe. He has been active in submitting comments and validated stability-indicating analytical methods to the U.S. Pharmacopeia and has been an invited speaker to FDA, university, and industry conferences.
Additional Faculty
Karen Lucas, Associate Director of North America Stability Management/APR Process, Johnson & Johnson Consumer Group
Carmelinda (Jing) Capucao, R&D Stability Manager, McNeil Consumer Products
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
n/a
|
|
|
|
|
|
|
|
Registration:
|
|
Please click here for registration information.
|
|
|
E-mail:
|
|
jmorbit@cfpa.com
|
|
|
|
|
|
|
|
|
As a result, strictly following the ICH stability guidance for NCEs is unwarranted and ignores this significant database of information that is typically available for OTC drug products. For OTC drug products covered by an OTC monograph or an ANDA, there is frequently years of proven experience with the drug substance as well as the drug product. It is this body of data that can often be used to justify a pre-market stability program.
This 2-day intensive course will provide an understanding of how the pre-market stability programs can be successfully managed while minimizing the overall timeline. Lectures will address the seven key GMP aspects of a stability program along with all of the relevant ICH, FDA, WHO and CHPA guidelines that cover drug product stability. Accelerated testing that allows the marketing of a new OTC drug product prior to the generation of long term, real time stability data and confirmation of the stability projections through an appropriate post-market stability program will also be covered.